Physician profile
Irit Hemed
NPI 1255398665
$5,785.38
in general payments reported to CMS, 2019-2025
35 companies · $933 in 2025
The $933 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,381 · 2020: $681 · 2021: $797 · 2022: $373 · 2023: $702 · 2024: $918 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,552.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $897.06 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $523.43 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $521.91 | 2019-2025 | |
| Amgen INC. | $387.45 | 2019-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $355.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $337.57 | 2019-2025 | Gardasil 9, Capvaxive |
| Abbvie INC. | $316.67 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $302.89 | 2019-2025 | Leqvio |
| Janssen Pharmaceuticals, INC | $278.13 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $230.47 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $219.40 | 2023-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $193.20 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $142.33 | 2019-2021 | |
| Esperion Therapeutics, INC. | $137.22 | 2021-2025 | Nexletol |
| Glaxosmithkline, LLC. | $126.40 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $95.23 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.35 | 2019-2020 | |
| Astellas Pharma US INC | $90.29 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $83.95 | 2022-2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.16 | 2020-2022 | |
| Exact Sciences Corporation | $50.14 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $45.68 | 2025 | Korlym |
| Braemar Manufacturing, LLC | $40.34 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $38.73 | 2019-2024 | Livalo |
| Medicure Pharma INC. | $33.74 | 2021-2025 | Zypitamag |
| Currax Pharmaceuticals LLC | $27.50 | 2022-2024 | Contrave |
| Axsome Therapeutics, INC. | $26.17 | 2025 | Auvelity |
| Lundbeck LLC | $23.09 | 2025 | Vyepti |
| Ibsa Pharma INC. | $19.10 | 2020 | |
| Horizon Therapeutics Plc | $16.49 | 2021 | |
| Radius Health, INC. | $16.44 | 2023 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $15.96 | 2020 | |
| Amneal Pharmaceuticals LLC | $15.58 | 2019 | |
| Alfasigma USA, INC. | $14.63 | 2020 | |
| Allergan, INC. | $12.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irit Hemed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.